Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease

Journal of Rheumatology

Volumn 45, Issue 9, 2018, Pages 1240-1248

  Jin, Yinzhu ^a,b   Kang, Eun Ha ^a,c   Brill, Gregory ^a,b   Desai, Rishi J ^a,b   Kim, Seoyoung C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Antirheumatic Drugs Cardiovascular Diseases; Biologic Disease Modifying; Comparative Safety Research; Rheumatoid Arthritis

Indexed keywords

ABATACEPT; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSURANCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICARE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VENOUS THROMBOEMBOLISM; INCIDENCE; MALE; MIDDLE AGED; REGISTER; RISK; VERY ELDERLY;

ABATACEPT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RISK; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 85052842421     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.170926     Document Type: Article

References (28)

1. Gabriel SE. Cardiovascular Morbidity and mortality in rheumatoid arthritis. Am J Med 2008;10 Suppl 1:S9-14.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005;52:402-11.
4. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89:33D-8D.
5. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
6. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.
7. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005;32:435-42.
8. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Annals Rheum Dis 2010;69:1920-5.
9. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology 2013;52:45-52.
10. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-9.
11. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008; 9:1121-8.
12. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
13. Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114-23.
14. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
15. Ursini F, Russo E, Letizia Hribal M, Mauro D, Savarino F, Bruno C, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine 2015;94:e888.
16. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al; Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014;37:1069-75.
17. Ursini F, Mauro D, Naty S, Gagliardi D, Grembiale RD. Improvement in insulin resistance after short-term treatment with abatacept: case report and short review. Clin Rheumatol 2012;31:1401-2.
18. Mathieu S, Couderc M, Glace B, Pereira B, Tournadre A, Dubost J-J, et al. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics 2013; 7:259-64.
19. Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813-8.
20. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
21. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104.
22. Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, et al. a systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:100-28.
23. Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims. Circ Cardiovasc Qual Outcomes 2014;7:611-9.
24. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228-34.
25. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption. In: Survival analysis: a self-learning text, third edition. New York: Springer New York; 2012:161-200.
26. Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, editors. Survival analysis: state of the art. Dordrecht: Springer Netherlands; 1992:237-47.
27. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nature Rev Rheumatol 2015;11:437-41.
28. Desai RJ, Solomon DH, Shadick N, Iannaccone C, Kim SC. Identification of smoking using Medicare data - a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf 2016;25:472-5.